title: Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Dutch Enuresis Study Group.
abstract: OBJECTIVE
  We evaluated the efficacy and safety of 2 oral doses of desmopressin compared to 20 micrograms. nasal spray and baseline values in the treatment of primary nocturnal enuresis.
  
  
  METHODS
  A multicenter study was done comparing oral dosages (200 and 400 micrograms.) of desmopressin (4-week, randomized, double-blind phase followed by 12 weeks of open label treatment with 400 micrograms.) to 20 micrograms. nasal spray in 66 adults and adolescents 12 to 45 years old with primary nocturnal enuresis.
  
  
  RESULTS
  No significant differences were found between the 2 doses of desmopressin tablets or between the tablets and 20 micrograms. nasal spray during the double-blind phase. However, patients who initially received 200 micrograms. desmopressin tablets experienced fewer wet nights after they completed 12 weeks of open label treatment when the dose was escalated to 400 micrograms. tablets. Those who received 400 micrograms. tablets initially maintained response during this phase. Desmopressin tablets were well tolerated at both dose levels: 96% of patients and 94% of physicians rated the tolerability as excellent.
  
  
  CONCLUSIONS
  Desmopressin tablets are an effective and safe alternative for treatment of nocturnal enuresis.
authors.affiliation: Department of Urology, University Hospital Maastricht, The Netherlands.
authors.forename: R A
authors.initials: RA
authors.lastname: Janknegt
authors.forename: H M
authors.initials: HM
authors.lastname: Zweers
authors.forename: K P
authors.initials: KP
authors.lastname: Delaere
authors.forename: A G
authors.initials: AG
authors.lastname: Kloet
authors.forename: S G
authors.initials: SG
authors.lastname: Khoe
authors.forename: H J
authors.initials: HJ
authors.lastname: Arendsen
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012076:Renal Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D012076:Renal Agents; D003894:Deamino Arginine Vasopressin